Lipid composition for delivering nucleic acid in vivo

By designing the composition and structure of specific lipid nanoparticles, the problem of poor nucleic acid immunogenicity and expression effects after nasal administration is solved, and efficient nucleic acid delivery and local immune response enhancement of nasal and respiratory mucosa administration is achieved.

CN118986928APending Publication Date: 2024-11-22LIVERNA THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411026303.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The immunogenicity and expression effects of nucleic acids after nasal or respiratory administration are weaker than intramuscular and subcutaneous administration, and the nucleic acids are unevenly distributed in the body, especially after nasal administration.

Method used

Lipid nanoparticles containing 25.0-50.0 mol % of cationic lipid, 6.0-40.0 mol % of phospholipid, 20.0-47.0 mol % of structural lipid and 1.0-5.0 mol % of polyethylene glycol modified lipids, were employed. It encapsulates nucleic acids and is used for nasal or respiratory mucosa administration. By adjusting parameters such as lipid composition and particle size, it improves the delivery efficiency and immunogenicity of nucleic acids.

Benefits of technology

It significantly improves the intracellular delivery efficiency and immunogenicity of nucleic acids after nasal administration, ensures efficient expression and distribution of nucleic acids on the nasal cavity and respiratory mucosa, and enhances the local immune response.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986928A_ABST
    Figure CN118986928A_ABST
Patent Text Reader

Abstract

The present invention relates to nasal, mucosal drug delivery systems, in particular to lipid compositions for in vivo delivery of nucleic acids comprising nucleic acids that can be used for mucosal administration of nucleic acids to treat or prevent diseases, such as infectious diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This disclosure relates to the field of nucleic acid delivery, and more specifically, to a lipid composition for in vivo delivery of nucleic acids. Background Technology

[0002] Lipid nanoparticles (LNPs) are typically composed of various lipids and are used in delivery systems to encapsulate mRNA and enhance its stability. This prevents extracellular degradation of mRNA and promotes its uptake and release into the cytoplasm. Lipid components include, but are not limited to, ionizable / cationic lipids, accessory lipids (such as neutral lipids and / or cholesterol), and lipids modified through PEGylation.

[0003] The emergence of LNPs is a milestone in the development of RNA therapy, successfully solving the challenges of protecting and delivering RNA. Due to their relatively easy and scalable production methods, LNPs are now used in cutting-edge mRNA vaccine candidates and widely used novel coronavirus vaccines.

[0004] The earliest LNP formulation was the siRNA vaccine, which was launched in 2018. When the dissociation constant (pKa) of ionizable cationic lipids is between 6.2 and 6.5, optimal liver targeting efficiency can be achieved via intravenous injection. The two subsequent COVID-19 mRNA vaccines clearly drew upon this principle. The nanoplatform technology was optimized for ionizable cationic lipids.

[0005] However, researchers found that when these drug delivery systems delivered the same nucleic acid through different routes of administration (intramuscular, intradermal, and nasal drops), the immunogenicity and expression in vivo varied. Nasal administration had a significantly weaker immunizing effect than intramuscular and subcutaneous administration, and after nasal administration, the delivered nucleic acid was distributed in large quantities in the throat and stomach of mice (G. Anderluzzi, et al. The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency, Journal of Controlled Release 342(2022)388-399.).

[0006] There is a need in the field for drugs to be administered via the nasal cavity or respiratory mucosa, thereby stimulating mucosal immunity and better protecting the body's drug delivery system. Summary of the Invention

[0007] In one aspect, this disclosure provides a lipid composition for in vivo delivery of nucleic acids, comprising lipid nanoparticles and nucleic acids encapsulated by the lipid nanoparticles.

[0008] In some embodiments, the lipid nanoparticles comprise 25.0-50.0 mol% cationic lipids, 6.0-40.0 mol% phospholipids, 20.0-47.0 mol% structural lipids, and 1.0-5.0 mol% polyethylene glycol-modified lipids, based on the total amount of all lipids in the lipid nanoparticles.

[0009] In some embodiments, the lipid nanoparticles comprise 25.0-50.0 mol% cationic lipids, 6.0-30.0 mol% phospholipids, 20.0-47.0 mol% structural lipids, and 1.0-5.0 mol% polyethylene glycol-modified lipids, based on the total amount of all lipids in the lipid nanoparticles.

[0010] In some embodiments, the lipid nanoparticles comprise 49.1 mol% cationic lipids, 27.9 mol% phospholipids, 20.1 mol% structural lipids, and 2.9 mol% polyethylene glycol-modified lipids, based on the total amount of all lipids in the lipid nanoparticles.

[0011] In some embodiments, the cationic lipid is selected from at least one compound of formula 1, formula 2, formula 3, formula 4.

[0012]

[0013]

[0014] In some embodiments, the cationic lipid is a compound as shown in Formula 2.

[0015] In some embodiments, the structural lipid is selected from at least one of cholesterol, coccosterol, sitosterol, ergosterol, campesterol, stigmasterol, lycopene, lycopene, lycopene, ursolic acid, and α-tocopherol.

[0016] In some implementations, the structural lipid is cholesterol.

[0017] In some embodiments, the phospholipid is selected from at least one of DSPC, DOPE, DLPC, DMPC, DOPC, DPPC, DUPC, POPC, DOPG, DPPG, DPPE, DMPE, DSPE, and DOTAP.

[0018] In some embodiments, the polyethylene glycol-modified lipid is selected from at least one of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, and PEG-modified dialkylglycerol.

[0019] In some embodiments, the PEG lipid is at least one of PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, PEG-DSPE, ceramide-PEG2000, or Chol-PEG2000 and PEG2000.

[0020] In some embodiments, the PEG lipid is PEG2000.

[0021] In some embodiments, the nucleic acid includes DNA molecules and / or RNA molecules.

[0022] In some embodiments, the DNA molecule includes a stranded DNA molecule and / or a circular DNA molecule.

[0023] In some embodiments, the RNA molecule includes mRNA or circular RNA.

[0024] In some embodiments, the mRNA molecule includes an open reading frame (ORF) whose nucleotide sequence is shown as one of Seq ID NO.4 or Seq ID NO.6.

[0025] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of which is shown in Seq ID NO.4.

[0026] In some embodiments, the lipid composition for in vivo delivery of nucleic acids is used for nasal or respiratory mucosal administration.

[0027] In some embodiments, the nasal administration includes nasal drops, nasal sprays, or nasal inhalation.

[0028] In some embodiments, the lipid nanoparticles have an average particle size of 60 nm to 300 nm. In some embodiments, the lipid nanoparticles have an average particle size of 60 nm to 100 nm. In some embodiments, the lipid nanoparticles have an average particle size of 60 nm to 90 nm. In some embodiments, the lipid nanoparticles have an average particle size of 60 nm. In some embodiments, the lipid nanoparticles have an average particle size of 60 nm.

[0029] In some embodiments, the polydispersity index of the lipid nanoparticles is 0 to 0.25. In some embodiments, the polydispersity index of the lipid nanoparticles is 0.10 to 0.20.

[0030] In some embodiments, the lipid nanoparticles have a Zeta potential of -20 mV to +20 mV. In some embodiments, the lipid nanoparticles have a Zeta potential of +10 mV to +20 mV.

[0031] In another aspect, this disclosure also provides a pharmaceutical composition comprising the lipid composition of this disclosure for in vivo delivery of nucleic acids, and optionally a pharmaceutically acceptable excipient.

[0032] In some embodiments, the lipid compositions or pharmaceutical compositions disclosed herein for in vivo delivery of nucleic acids are used for nasal or respiratory mucosal administration.

[0033] The formulation of claim 8, wherein the excipient is 1×PBS buffer, and the buffer solution is pH 7.4 ± 0.05.

[0034] In some embodiments, the pharmaceutical composition is used for nasal administration, and the nucleic acid concentration in the pharmaceutical composition is 800-1000 μg / mL.

[0035] In some embodiments, the pharmaceutical composition is used for administration to the respiratory mucosa, and the nucleic acid concentration in the pharmaceutical composition is 400-600 μg / mL. Attached Figure Description

[0036] To more clearly illustrate the technical solutions in the specific embodiments of this disclosure or the prior art, the drawings used in the description of the specific embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of this disclosure. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.

[0037] Figure 1 The results show the cell delivery efficiency of formulations F1–F5 used for in vivo delivery of nucleic acids.

[0038] Figure 2 Fluorescence detection results (mice) 6 hours after intranasal administration of formulations F1–F5 for in vivo delivery of nucleic acids.

[0039] Figure 3 The results of fluorescence detection 6 hours after intranasal administration of formulations F1-F5 for in vivo delivery of nucleic acids.

[0040] Figure 4The results show the cell delivery efficiency of formulations F2–F3 and F6, which are used for in vivo delivery of nucleic acids.

[0041] Figure 5 Fluorescence detection results (mice) 6 h after intranasal administration of formulations F2–F3 and F6 for in vivo delivery of nucleic acids.

[0042] Figure 6 Fluorescence detection results at 6 hours after nasal instillation of formulations F2–F3 and F6, which are used for in vivo delivery of nucleic acids.

[0043] Figure 7 The results show the cell delivery efficiency of formulations F3, F7-F8, which are used for in vivo delivery of nucleic acids.

[0044] Figure 8 Fluorescence detection results (mice) 6 hours after intranasal administration of formulations F3, F7-F8 for in vivo delivery of nucleic acids.

[0045] Figure 9 The results are fluorescence detection results 6 hours after intranasal administration of formulations F3, F7-F8, which are used for in vivo delivery of nucleic acids.

[0046] Figure 10 The results show the cell delivery efficiency of formulations F8–F10, used for in vivo delivery of nucleic acids.

[0047] Figure 11 Fluorescence detection results (mice) 6 hours after intranasal administration of formulations F8-F10 for in vivo delivery of nucleic acids.

[0048] Figure 12 The results are fluorescence detection results 6 hours after intranasal administration of formulations F8-F10 for in vivo delivery of nucleic acids.

[0049] Figure 13 The results show the serum specific IgG and IgA titers after intranasal administration of formulations F1, F8, and F11 for in vivo delivery of nucleic acids (nasal administration).

[0050] Figure 14 Results of bronchopulmonary lavage fluid and nasal lavage fluid specific IgA titers after intranasal administration of formulations F1, F8 and F11 for in vivo delivery of nucleic acids (nasal administration).

[0051] Figure 15 The results show the serum-specific IgG titers and nasal lavage fluid-specific IgA results after nebulization of formulations F1 and F8, which are used for in vivo delivery of nucleic acids.

[0052] Figure 16 The results show the detection of lung lymphocytes in mice after nebulization of formulations F1 and F8, which are used for in vivo delivery of nucleic acids. Detailed Implementation

[0053] Unless otherwise described, all techniques and scientific methods used in this disclosure have the same meaning as commonly understood by one of ordinary skill in the art. For purposes of interpreting this specification, the descriptions in this disclosure will apply, and where appropriate, the singular will be used in conjunction with the plural, and vice versa. All patents, applications, published applications, and other publications are incorporated herein by reference in their entirety. If any description in this disclosure is in conflict with any document incorporated herein by reference, the description in this disclosure hereinafter shall prevail.

[0054] In this disclosure, "lipid nanoparticles" refers to particles having at least one nanometer (nm) scale size (e.g., 1 to 1,000 nm) containing one or more types of lipid molecules. In some embodiments, the lipid nanoparticles contain non-lipid molecules partially or completely encapsulated within a lipid shell. In some embodiments, the non-lipid molecules are nucleic acids (e.g., mRNA encoding viral proteins), and the lipid component of the lipid nanoparticles contains at least one cationic lipid. Without being bound by theory, the interaction between cationic lipids and nucleic acids during lipid nanoparticle formation can promote the entry and / or encapsulation of nucleic acids into the lipid nanoparticles.

[0055] In this disclosure, "cationic lipid" refers to a lipid that carries a positive charge at any pH or hydrogen ion activity in its environment, or is capable of carrying a positive charge in response to the pH or hydrogen ion activity of its environment. In this disclosure, "cation" encompasses both "permanent cation" and "cationizable." In some embodiments, the positive charge in the cationic lipid is caused by the presence of quaternary nitrogen atoms.

[0056] In this disclosure, "pharmaceutically acceptable carriers, diluents, or excipients" include, but are not limited to, any adjuvants, carriers, excipients, gliding agents, sweeteners, diluents, preservatives, dyes / colorants, flavor enhancers, surfactants, wetting agents, dispersants, suspending agents, stabilizers, isotonic agents, solvents, or emulsifiers approved by national drug regulatory authorities (such as the US FDA and China CDE) for use in humans or livestock.

[0057] In this disclosure, "mol%" refers to the molar percentage of a component relative to the total moles of all lipid components in the lipid nanoparticle (e.g., the total moles of cationic lipids, phospholipids, structured lipids, and polyethylene glycol-modified lipids).

[0058] In this disclosure, “about” or “approximately” means an acceptable error in a particular value as determined by a person of ordinary skill, depending in part on how the value is measured or determined. In some embodiments, “about” or “approximately” in this disclosure means within 1, 2, 3, or 4 standard deviations. In some embodiments, “about” or “approximately” in this disclosure means within 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.05%, or less of a given value or range. As used herein, when “about” is used in conjunction with a numerical range, “about” in this disclosure is intended to apply to both ends of such modified ranges (e.g., “about 5 to 10” means “about 5 to about 10”).

[0059] This document provides lipid compositions for in vivo delivery of nucleic acids, wherein the formulation comprises lipid nanoparticles in which nucleic acids are formulated, and delivery of the lipid nanoparticles to host cells, wherein the delivered nucleic acid is expressed in the host cells. In some embodiments, host cells are isolated and delivery is performed by contacting the host cells with the lipid composition for in vivo delivery of nucleic acids under suitable conditions in vitro, wherein the nucleic acid is expressed by the host cells. In some embodiments, the host cells are in their native environment within a subject, and delivery is performed by administering an appropriate amount of the lipid composition for in vivo delivery of nucleic acids to the subject, wherein the nucleic acid is expressed in the subject's host cells.

[0060] In some embodiments, therapeutic and / or prophylactic agents encapsulated in lipid nanoparticles can be delivered to host cells in vitro, for example, by contacting host cells with a lipid composition for in vivo delivery of nucleic acids, or in vivo, for example, by administering the lipid composition for in vivo delivery of nucleic acids to a subject containing host cells. In some embodiments, after delivery, the therapeutic nucleic acids encapsulated in the lipid nanoparticles can be expressed by endogenous transcription and translation mechanisms within the host cells.

[0061] Lipid nanoparticles can be characterized using a variety of methods. For example, microscopy (e.g., transmission electron microscopy or scanning electron microscopy) can be used to examine the morphology and size distribution of lipid nanoparticles. Dynamic light scattering or potentiometry (e.g., potentiometric titration) can be used to measure the zeta potential. Dynamic light scattering can also be used to determine particle size. Instruments such as the Zetasizer Nano ZS (Malvem Instruments Ltd, Malvem, Worcestershire, UK) can also be used to measure multiple characteristics of lipid nanoparticles, such as particle size, polydispersity index, and zeta potential.

[0062] In some embodiments, the average particle size of the lipid nanoparticles can be between tens of nanometers and hundreds of nanometers. For example, the average particle size can be from about 60 nm to about 300 nm. In some embodiments, the average particle size of the lipid nanoparticles can be from about 80 nm to about 100 nm, or from about 80 nm to about 90 nm.

[0063] Unless otherwise specified, when the lipid compositions described herein for in vivo nucleic acid delivery are prepared as nasal sprays or inhalation sprays, or used for nasal spray or aerosol inhalation administration, the average particle size of the lipid nanoparticles is the average particle size before administration. In some embodiments, the inhalation sprays of this disclosure include an atomizer device and a lipid composition for in vivo nucleic acid delivery contained within the atomizer device, wherein the average particle size of the lipid nanoparticles is the average particle size measured when contained within the atomizer device, i.e., the average particle size measured before administration.

[0064] Lipid nanoparticles can be relatively homogeneous. The polydispersity index (PDI) can be used to indicate the homogeneity of lipid nanoparticles, such as their particle size distribution. A smaller PDI (e.g., less than 0.3) generally indicates a narrower particle size distribution. The PDI of lipid nanoparticles can be from about 0.00 to about 0.25. In some embodiments, the PDI of lipid nanoparticles can be from about 0.00 to about 0.10.

[0065] The zeta potential of lipid nanoparticles can be used to indicate the potentiodynamics of a composition. For example, the zeta potential describes the surface charge of the lipid nanoparticles. Lipid nanoparticles with a low absolute value of positive or negative charge are preferred because substances with a high absolute value of charge can interact undesirably with cells, tissues, and other components in the body. In some embodiments, the zeta potential of the lipid nanoparticles may be from about -20 mV to about +20 mV, or from about +10 mV to about +20 mV.

[0066] Encapsulation efficiency describes the amount of nucleic acid encapsulated by lipid nanoparticles or otherwise associated with lipid nanoparticles after preparation, relative to the initial amount of nucleic acid provided. High encapsulation efficiency (e.g., close to 100%) is preferred. In some embodiments, the lipid nanoparticles contain nucleic acid as a therapeutic agent, and the encapsulation efficiency of said nucleic acid is at least about 80%. In some embodiments, the encapsulation efficiency of said nucleic acid is at least about 90%. In some embodiments, the encapsulation efficiency of said nucleic acid is at least about 98%.

[0067] Lipid nanoparticles typically consist of four types of lipids: (1) cationic lipids, (2) polyethylene glycol (PEG) lipids, (3) cholesterol, and (4) structural lipids. The first component, cationic lipids, generally consists of a cationic head group and a lipid tail, located at the core of the nucleic acid-containing lipid nanoparticle. The second component, PEG lipids, has PEG chains anchored to the lipid head group. The third component is cholesterol, which participates in the intracellular delivery of lipid nanoparticles. The fourth component, structural lipids, is mainly present on the surface of lipid nanoparticles and contributes to nucleic acid packaging and nanoparticle stability. Furthermore, the second, third, and fourth components are often referred to as accessory lipids in lipid nanoparticles, which can promote structural transformation of lipid nanoparticles in the endosome and stimulate the cytoplasmic release of nucleic acids.

[0068] Phospholipids are structural lipids in lipid nanoparticles, mainly found on the surface of lipid nanoparticles, and contribute to nucleic acid packaging and nanoparticle stability. Unbound by theory, phospholipids are expected to assemble into one or more lipid bilayer structures. In some embodiments, the phospholipids of this disclosure are selected from at least one of 1,2-distearyl-sn-glycerol-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycerol-3-phosphoethanolamine (DOPE), 1,2-dilinoleoyl-sn-glycerol-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycerol-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycerol-3-phospho-racemic-(1-glycerol) sodium salt (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearyl-phosphatidylethanolamine (DSPE), and 1,2-dioleoyl-3-co-acylcholine (DOTAP).

[0069] In this disclosure, the terms "nucleic acid" and "polynucleotide" are used interchangeably to refer to polymers of deoxyribonucleotides (DNA) or polymers of ribonucleotides (RNA). The terms "nucleic acid sequence," "polynucleotide sequence," and "nucleotide sequence" are used interchangeably to indicate the sequence of nucleotides in a polynucleotide. Those skilled in the art will understand that the DNA coding strand (sense strand) and its encoded RNA can be considered to have the same nucleotide sequence, and that the deoxythymidine nucleotide in the DNA coding strand sequence corresponds to the uridine nucleotide in its encoded RNA sequence.

[0070] The open reading frame (ORF) described in this disclosure is a continuous DNA or RNA segment that begins with a start codon (such as ATG or AUG) and ends with a stop codon (such as TAA, TAG, or TGA, or UAA, UAG, or UGA).

[0071] In some embodiments, based on the provided mRNA open reading frame sequence, those skilled in the art can obtain the corresponding circular RNA open reading frame sequence and, in accordance with the content of published documents such as CN202180048567.4, prepare a complete circular RNA sequence encoding the same amino acid sequence. In some embodiments, based on the provided mRNA sequence, those skilled in the art can obtain the corresponding DNA sequence (e.g., uracil to thymine conversion). Similarly, based on the provided DNA sequence, those skilled in the art can obtain the corresponding RNA sequence (e.g., thymine to uracil conversion). In some embodiments, based on the provided RNA or DNA sequence, those skilled in the art can obtain the corresponding amino acid sequence.

[0072] In some embodiments, the mRNA described in this disclosure consists of a sequence comprising a 5' cap, a 5' UTR, an ORF, a 3' UTR, and a 3' poly(A) tail, from the 5' end to the 3' end.

[0073] The 5' untranslated region (UTR) described in this disclosure refers to the sequence of mRNA that does not encode a polypeptide, located directly upstream (i.e., 5') of the start codon (i.e., the first codon of the mRNA transcript translated by ribosomes). When an RNA transcript is generated, the 5' UTR may contain a promoter sequence. Such promoter sequences are known in the art. RNA sequences of the 5' UTR are shown in Seq ID No. 16 and Seq ID No. 1, or 5' UTR sequences disclosed prior to the date of this application may also be incorporated into this disclosure.

[0074] The 3' untranslated region (UTR) described in this disclosure refers to the sequence of mRNA that does not encode a polypeptide, located downstream of a stop codon. The RNA sequence of the 3' UTR is shown in Seq ID NO.2, or a 3' UTR sequence disclosed prior to the date of this application may also be incorporated into this disclosure.

[0075] The poly(A) tail described in this disclosure is a downstream sequence of the 3'UTR of mRNA containing multiple consecutive adenosine monophosphates (ATPs). The poly(A) tail may contain 10 to 300 ATPs. In cells and / or in vivo, the poly(A) tail serves to protect mRNA from enzymatic degradation and to facilitate transcription termination and / or mRNA export from the nucleus and translation.

[0076] In this disclosure, the 5' cap can be co-transcribed into RNA during in vitro transcription (e.g., using an anti-reverse cap analog "ARCA"), or it can be ligated into RNA post-transcriptionally using a capping enzyme. The 5' cap is selected from ARCA, mCAP, dmCAP, tmCAP, m7G(5')ppp(5')(2'OMeA)pG, m7(3'OMeG)(5')ppp(5')(2'OMeA)pG, m7(3'OMeG)(5')ppp(5')(2'OMeG)pG, m7G(5')ppp(5')(2'OMeG)pG, or dmCAP. In some embodiments, the 5' cap is m7Gppp(5')ppp(5')(2'OMeA)pG.

[0077] In some embodiments, one or more uridines in the mRNA are replaced with the modified nucleoside N1-methyl-pseudouridine (m1ψ).

[0078] In another aspect, this disclosure also provides a pharmaceutical composition comprising the lipid composition of this disclosure for in vivo delivery of nucleic acids, and optionally a pharmaceutically acceptable excipient. In some embodiments, the lipid composition or pharmaceutical composition of this disclosure for in vivo delivery of nucleic acids is intended for nasal or respiratory mucosal administration.

[0079] Nasal drug delivery systems refer to a class of formulations that are administered via the nasal cavity to exert local or systemic therapeutic or preventative effects. They are particularly suitable for drugs requiring high local expression in the nasal cavity or those needing to avoid the first-pass effect in the liver. The advantages of nasal drug delivery include a large nasal mucosa surface area and rich blood supply, resulting in rapid drug absorption and a quick onset of action. Furthermore, it exhibits low first-pass effect in the liver, low systemic toxicity, and high bioavailability.

[0080] Common dosage forms for nasal drug delivery include nasal drops, nasal sprays, powders, gels, and emulsions. Among these, nasal sprays offer the widest diffusion and dispersion area across the nasal mucosa. Currently, commonly used nebulizers include metered-dose inhalers (MDI), dry powder inhalers (DPI), and nebulizers. After nasal spraying, the drug deposits in the anterior nasal cavity, with only a small portion being slowly cleared into the throat. This prolongs the drug's residence time in the nasal cavity, which is beneficial for absorption and improves bioavailability.

[0081] Respiratory mucosal administration refers to the administration of drugs through special devices to exert systemic or local effects via the deep respiratory tract, cavities, and mucous membranes.

[0082] Common dosage forms for respiratory mucosal administration include inhaled aerosols, inhaled powders, inhaled sprays, inhaled liquid preparations, and vapor-convertible preparations. Inhaled sprays are a traditional method of administration, referring to solutions, suspensions, or emulsions that produce an aerosol for inhalation using a pre-measured or metered-dose nebulizer. During use, the contents are released as a mist using pressure from a manual pump, ultrasonic vibration, high-pressure gas, or other methods, allowing a certain amount of atomized liquid to be inhaled in the form of an aerosol during a single breath. It combines the characteristics of nebulized drug delivery with the avoidance of propellants, resulting in lower cost, rapid onset of action, ease of use, and safety. However, the larger droplets require a larger volume of medication.

[0083] In another aspect, this disclosure also provides a method for treating or preventing a disease or condition, comprising administering a nucleic acid to a subject in a multi-dose regimen, wherein at least one dose is administered via a mucosal route to the formulation or pharmaceutical composition of this disclosure.

[0084] In another aspect, this disclosure also provides a nasal drop or nasal spray comprising the lipid composition of this disclosure for in vivo delivery of nucleic acids and a pharmaceutically acceptable excipient.

[0085] In another aspect, this disclosure also provides an inhalation spray comprising the lipid composition of this disclosure for in vivo delivery of nucleic acids and pharmaceutically acceptable excipients.

[0086] The pharmaceutically acceptable excipients contained in the pharmaceutical compositions, inhaled sprays, nasal drops, or nasal sprays disclosed herein may include propellants such as trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethane, 1,1,1,2-tetrafluoroethane, etc. The pharmaceutically acceptable excipients may also include one or more of water, sugar solutions, electrolyte solutions, and amino acid solutions. For example, the pharmaceutically acceptable excipients include one or more of water, Ringer's solution, glucose solution, glucose sodium chloride solution, isotonic sodium chloride solution, fructose solution, dextran, amino acid solutions, heparin solution, mannitol solution, sodium bicarbonate solution, and PBS buffer.

[0087] In another aspect, this disclosure provides a method for preparing the aforementioned lipid composition for in vivo delivery of nucleic acids, characterized in that it comprises: mixing the mRNA and lipid nanoparticles to form a lipid composition for in vivo delivery of nucleic acids.

[0088] In some embodiments, the method for preparing the lipid composition for in vivo delivery of nucleic acids involves dissolving mRNA in a buffer solution to obtain an aqueous phase, measuring each lipid component of liposome nanoparticles and dissolving them in an organic solvent to obtain an organic phase, mixing the aqueous phase and the organic phase, and then removing the organic phase to obtain the lipid composition for in vivo delivery of nucleic acids.

[0089] In some embodiments, the volume ratio of the aqueous phase to the organic phase is 1:2 to 4, preferably 1:3.

[0090] In some embodiments, the buffer solution comprises citrate buffer or sodium acetate, preferably citrate buffer.

[0091] In some embodiments, the pH of the buffer solution is 3 to 7, preferably 4.

[0092] In some embodiments, the concentration of mRNA in the aqueous phase is 0.05 mg / mL to 0.5 mg / mL, preferably 0.1 mg / mL.

[0093] In some embodiments, the organic solvent is selected from C1 to C4 lower alcohols, preferably anhydrous ethanol.

[0094] In some embodiments, the concentration of the lipid component in the organic phase is 5 mg / mL to 7 mg / mL, preferably 6 mg / mL.

[0095] In some implementations, microfluidic mixing of aqueous and organic phases is used, and tangential flow filtration of organic solvents is employed;

[0096] Preferably, the flow rate of the microfluidic system is >3 mL / min, and more preferably 12 mL / min.

[0097] Example 1

[0098] Preparation of mRNA

[0099] 1. RNA sequences were synthesized using linearized plasmid DNA as a template via in vitro transcription (IVT):

[0100] Add the following to the reactor: 1.0 μg template DNA, 2.0 μL 10× transcription buffer, 0.2 μL NTPs (25 mM each), 20 U RNase inhibitor, 3000 U T7 RNA polymerase, and 0.0 μL dH2O; incubate at 37°C for 3 to 5 hours. The transcription buffer consists of: 400 mM Tris-HCl pH 8.0, 190 mM MgCl2, 50 mM MTT, and 10 mM spermidine.

[0101] 2. Enzymatic capping:

[0102] The RNA obtained by in vitro transcription in the above steps was purified, and 60 μg of the obtained RNA was mixed with 72 μL dH2O and incubated at 65°C for 5 minutes to denature the RNA. The RNA-denatured mixture was then transferred to ice.

[0103] Mix the RNA denaturation mixture, 10.0 μL 10× capping buffer, 5.0 μL 20 mM MTGTP, 2.5 μL 20 mM MS-adenosylmethionine, 100 U RNase inhibitor, 400 U 2'-O-methyltransferase, 40 U vaccinia capping enzyme, and 28 μL dH2O, and incubate at 37°C for 30 minutes.

[0104] The end-capping buffer consists of 0.5 M Tris-HCl (pH 8.0), 60 mg M KCl, and 12.5 mg M MgCl2.

[0105] 3. Polyadenylation tailing reaction:

[0106] If the template DNA lacks a poly-T tail or if a longer polyadenylated tail is desired, a polyadenylated tailing reaction can be performed after enzymatic capping. Mix 100 μL of the enzymatically capped RNA, 20 U of RNase inhibitor, 12.0 μL of 10× tailing buffer, 6.0 μL of 20 mM ATP, 20 U of polyadenylated polymerase, and 123 μL of dH2O, and incubate at 37°C for 30 min.

[0107] The tailing buffer consists of 0.5 M Tris-HCl (pH 8.0), 2.5 M NaCl, and 100 mM MgCl2.

[0108] Example 2

[0109] Preparation of lipid compositions for in vivo delivery of nucleic acids

[0110] This embodiment provides a lipid composition for in vivo delivery of nucleic acids, comprising mRNA encoding a fluorescein, wherein the mRNA includes a 5' UTR, an ORF region, a 3' UTR, and a poly(A) tail from its 5' to 3' ends. The nucleotide sequence of the 5' UTR is shown in SEQ ID NO.1, the nucleotide sequence of the 3' UTR is shown in SEQ ID NO.2, and the nucleotide sequence of the poly(A) tail is shown in SEQ ID NO.3.

[0111] The lipid composition for in vivo delivery of nucleic acids comprises, by molar percentage, 49.1% cationic lipid of Formula 1, 6.9% structural lipid DSPC, 41.1% cholesterol, and 2.9% polyethylene glycol 2000.

[0112] The preparation method is as follows:

[0113] (a) Dissolve the RNA in a citrate buffer at pH 4 and adjust the concentration to 0.1 mg / mL to obtain the aqueous phase.

[0114] (b) Dissolve cationic lipids, structural lipids, cholesterol and polyethylene glycol lipids in anhydrous ethanol according to the formulation amount, and adjust the concentration of lipid components in the organic phase to 6 mg / mL to obtain the organic phase.

[0115] (c) The aqueous phase from step (a) and the organic phase from step (b) were mixed at a volume ratio of 1:3 using a microfluidic device at a flow rate of 12 mL / min. The mixture was immediately diluted 100 times with a mixed solution and the ethanol component in the solution was removed by tangential flow filtration (TFF). The mixture was then concentrated to obtain lipid composition F1 for in vivo delivery of nucleic acids.

[0116] Example 3

[0117] Preparation of lipid compositions for in vivo delivery of nucleic acids

[0118] This embodiment provides a lipid composition for in vivo delivery of nucleic acids, comprising mRNA encoding a fluorescein, wherein the mRNA includes a 5' UTR, an ORF region, a 3' UTR, and a poly(A) tail from its 5' to 3' ends. The nucleotide sequence of the 5' UTR is shown in SEQ ID NO.1, the nucleotide sequence of the 3' UTR is shown in SEQ ID NO.2, and the nucleotide sequence of the poly(A) tail is shown in SEQ ID NO.3.

[0119] The lipid composition for in vivo delivery of nucleic acids comprises, by molar percentage, 49.1% cationic lipid of Formula 2, 6.9% structural lipid DSPC, 41.1% cholesterol, and 2.9% polyethylene glycol 2000.

[0120] The preparation method is as follows:

[0121] (a) Dissolve the RNA in a citrate buffer at pH 4 and adjust the concentration to 0.1 mg / mL to obtain the aqueous phase.

[0122] (b) Dissolve cationic lipids, structural lipids, cholesterol and polyethylene glycol lipids in anhydrous ethanol according to the formulation amount, and adjust the concentration of lipid components in the organic phase to 6 mg / mL to obtain the organic phase.

[0123] (c) The aqueous phase from step (a) and the organic phase from step (b) are mixed at a volume ratio of 1:3 using a microfluidic device at a flow rate of 12 mL / min. The mixture is immediately diluted 100 times with a mixed solution and the ethanol component in the solution is removed by tangential flow filtration (TFF). The mixture is then concentrated to obtain lipid composition F2 for in vivo delivery of nucleic acids.

[0124] Example 4

[0125] Preparation of lipid compositions for in vivo delivery of nucleic acids

[0126] This embodiment provides a lipid composition for in vivo delivery of nucleic acids, comprising mRNA encoding a fluorescein, wherein the mRNA includes a 5' UTR, an ORF region, a 3' UTR, and a poly(A) tail from its 5' to 3' ends. The nucleotide sequence of the 5' UTR is shown in SEQ ID NO.1, the nucleotide sequence of the 3' UTR is shown in SEQ ID NO.2, and the nucleotide sequence of the poly(A) tail is shown in SEQ ID NO.3.

[0127] The lipid composition for in vivo delivery of nucleic acids comprises, by molar percentage, 49.1% cationic lipid of Formula 2, 6.9% structural lipid DOTAP, 41.1% cholesterol, and 2.9% polyethylene glycol 2000.

[0128] The preparation method is as follows:

[0129] (a) Dissolve the RNA in a citrate buffer at pH 4 and adjust the concentration to 0.1 mg / mL to obtain the aqueous phase.

[0130] (b) Dissolve cationic lipids, structural lipids, cholesterol and polyethylene glycol lipids in anhydrous ethanol according to the formulation amount, and adjust the concentration of lipid components in the organic phase to 6 mg / mL to obtain the organic phase.

[0131] (c) The aqueous phase from step (a) and the organic phase from step (b) were mixed at a volume ratio of 1:3 using a microfluidic device at a flow rate of 12 mL / min. The mixture was immediately diluted 100 times with a mixed solution and the ethanol component in the solution was removed by tangential flow filtration (TFF). The mixture was then concentrated to obtain lipid composition F3 for in vivo delivery of nucleic acids.

[0132] Example 5

[0133] Preparation of lipid compositions for in vivo delivery of nucleic acids

[0134] This embodiment provides a lipid composition for in vivo delivery of nucleic acids, comprising mRNA encoding a fluorescein, wherein the mRNA includes a 5' UTR, an ORF region, a 3' UTR, and a poly(A) tail from its 5' to 3' ends. The nucleotide sequence of the 5' UTR is shown in SEQ ID NO.1, the nucleotide sequence of the 3' UTR is shown in SEQ ID NO.2, and the nucleotide sequence of the poly(A) tail is shown in SEQ ID NO.3.

[0135] The lipid composition for in vivo delivery of nucleic acids comprises, by molar percentage, 49.1% cationic lipid of formula 3, 6.9% structural lipid DOTAP, 41.1% cholesterol, and 2.9% polyethylene glycol 2000.

[0136] The preparation method is as follows:

[0137] (a) Dissolve the RNA in a citrate buffer at pH 4 and adjust the concentration to 0.1 mg / mL to obtain the aqueous phase.

[0138] (b) Dissolve cationic lipids, structural lipids, cholesterol and polyethylene glycol lipids in anhydrous ethanol according to the formulation amount, and adjust the concentration of lipid components in the organic phase to 6 mg / mL to obtain the organic phase.

[0139] (c) The aqueous phase from step (a) and the organic phase from step (b) were mixed at a volume ratio of 1:3 using a microfluidic device at a flow rate of 12 mL / min. The mixture was immediately diluted 100 times with a mixed solution and the ethanol component in the solution was removed by tangential flow filtration (TFF). The mixture was then concentrated to obtain lipid composition F4 for in vivo delivery of nucleic acids.

[0140] Example 6

[0141] Preparation of lipid compositions for in vivo delivery of nucleic acids

[0142] This embodiment provides a lipid composition for in vivo delivery of nucleic acids, comprising mRNA encoding a fluorescein, wherein the mRNA includes a 5' UTR, an ORF region, a 3' UTR, and a poly(A) tail from its 5' to 3' ends. The nucleotide sequence of the 5' UTR is shown in SEQ ID NO.1, the nucleotide sequence of the 3' UTR is shown in SEQ ID NO.2, and the nucleotide sequence of the poly(A) tail is shown in SEQ ID NO.3.

[0143] The lipid composition for in vivo delivery of nucleic acids comprises, by molar percentage, 24.1% cationic lipid of Formula 4, 38.9% structural lipid DOTAP, 34.1% cholesterol, and 2.9% polyethylene glycol 2000.

[0144] The preparation method is as follows:

[0145] (a) Dissolve the RNA in a citrate buffer at pH 4 and adjust the concentration to 0.1 mg / mL to obtain the aqueous phase.

[0146] (b) Dissolve cationic lipids, structural lipids, cholesterol and polyethylene glycol lipids in anhydrous ethanol according to the formulation amount, and adjust the concentration of lipid components in the organic phase to 6 mg / mL to obtain the organic phase.

[0147] (c) The aqueous phase from step (a) and the organic phase from step (b) were mixed at a volume ratio of 1:3 using a microfluidic device at a flow rate of 12 mL / min. The mixture was immediately diluted 100 times with a mixed solution and the ethanol component in the solution was removed by tangential flow filtration (TFF). The mixture was then concentrated to obtain lipid composition F5 for in vivo delivery of nucleic acids.

[0148] Example 7

[0149] I. Determination of the delivery efficiency of lipid compositions for in vivo nucleic acid delivery in cells

[0150] Human embryonic kidney cells 293 (HEK293) were cultured in a 5% CO2 incubator at 37°C. When the cells reached the logarithmic growth phase, they were digested with trypsin, collected, and stored at a cell density of 5 × 10⁻⁶ cells / year. 3 Inoculate one well per well into a 96-well plate and incubate overnight.

[0151] Luciferase mRNA positive control group: Add Opti-MEM™ Medium and transfection reagent to 1.5 mL centrifuge tubes, mix well, and let stand for 10 min. Record this as solution A. Add Opti-MEM™ Medium and mRNA to 1.5 mL centrifuge tubes, mix well, and let stand for 5 min. Record this as solution B. Add solution A to solution B, mix well, and let stand for 5 min. Then, add 100 μL of the mixture of solution A and B dropwise to 96-well cells.

[0152] Formulation group: First, dilute the formulation in Opti-MEM™ Medium, and add 100 μL of the liquid dropwise into 96-well plate cells.

[0153] PBS negative control group: Add the same volume of PBS to Opti-MEM™ Medium, and then add 100 μL of the liquid dropwise to the cells in a 96-well plate. Each group is in triplicate and incubated in a 37°C, 5% CO2 incubator.

[0154] After 24 hours, according to the test kit, add 100 μL of reagent to each well, let stand for 10 minutes, mix thoroughly, and then perform the test using an ELISA reader within 10 minutes.

[0155] II. Determination of delivery efficiency of lipid compositions for in vivo nucleic acid delivery in mice

[0156] Female Balb / c mice, 6 weeks old and weighing 20-25g, were purchased from Zhuhai Baishitong Biotechnology Co., Ltd.

[0157] Animals were randomly assigned to groups of 3, with PBS serving as the negative control group. The lipid compositions F1–F5 prepared in Examples 2–6 for in vivo nucleic acid delivery were taken and 1×PBS buffer (pH 7.4 ± 0.05) was used to adjust the mRNA concentration in formulations F1–F5 to 900 μg / mL.

[0158] F1 to F5 were administered via nasal drops (nasal administration). Six hours after administration, D-fluorescein potassium salt was injected intraperitoneally, and fluorescence was detected in the nasal cavity of the mice using a small animal imaging system.

[0159] The lipid compositions F1-F5 prepared in Examples 2-6 for in vivo nucleic acid delivery were used to test their delivery efficiency in cells. The results are shown in the table below. Figure 1 . Figure 1 The above Fluc represents the experimental results of the Luciferase mRNA positive control group.

[0160] Compared to the negative control, the lipid compositions for in vivo nucleic acid delivery in groups F1–F5 were all successfully expressed in cells, and the delivery efficiency of the lipid compositions for in vivo nucleic acid delivery in groups F2–F5 was higher than that in group F1. The lipid compositions F2 and F3 prepared from cationic lipids of Formula 2 for in vivo nucleic acid delivery showed higher delivery efficiency in cells.

[0161] The fluorescence detection results 6 hours after drug administration are shown in the figures below. Figure 2 and Figure 3 .

[0162] from Figure 2 As can be seen above, luciferin expression was observed in the nasal cavity of most mice 6 hours after drug administration. Furthermore, the lipid compositions (F2 and F3) prepared from cationic lipids of Formula 2 for in vivo nucleic acid delivery showed higher expression levels in the nasal cavity at 6 hours compared to other groups.

[0163] Based on the expression levels of lipid compositions for in vivo nucleic acid delivery in cells and in vivo, the expression levels of lipid compositions (F2 and F3) prepared from cationic lipids of Formula 2 for in vivo nucleic acid delivery were higher than those of cationic lipids in other groups.

[0164] Example 8

[0165] The lipid compositions F1-F5 prepared in Examples 2-6 for in vivo nucleic acid delivery were used, and the particle size, PDI, and Zeta potential of the formulations were measured using a particle size analyzer. The encapsulation efficiency of the formulations was then measured using a fluorescent dye. The results are shown in Table 1.

[0166] Table 1

[0167] preparation Particle size (nm) PDI Zeta potential (mV) Encapsulation efficiency (%) F1 79 0.09 0.64 95.7 F2 79 0.16 -1.41 96.8 F3 79 0.14 5.92 97.3 F4 110 0.13 9.45 90.1 F5 81 0.12 15.68 99.6

[0168] Example 9

[0169] A lipid composition F6 for in vivo delivery of nucleic acids was prepared according to the method described in Example 6, wherein the lipids, by molar percentage, are 49.1% cationic lipid of Formula 2, 6.9% structural lipid DOPE, 41.1% cholesterol, and 2.9% polyethylene glycol 2000.

[0170] The lipid compositions F2-F3 for in vivo nucleic acid delivery prepared in Examples 3-4 and the lipid composition F6 for in vivo nucleic acid delivery prepared in this example were used to detect the delivery efficiency in cells and in mice according to the method described in Example 7. In the detection of delivery efficiency in mice, the mRNA concentration in preparations F2-F3 and F6 was adjusted to 900 μg / mL with 1×PBS buffer (pH 7.4±0.05).

[0171] Results of cell delivery efficiency assay are shown below Figure 4 Compared with the negative control, the lipid compositions for in vivo nucleic acid delivery in groups F3, F2, and F6 were successfully expressed in cells. The expression efficiency of the lipid composition for in vivo nucleic acid delivery in group F3 was higher than that in groups F2 and F6. Six hours after administration, D-fluorescein potassium was injected intraperitoneally, and the results of fluorescence detection using a small animal imaging system are shown below. Figure 5 and Figure 6 .

[0172] from Figure 5 and Figure 6 As can be seen above, luciferin expression was observed in the nasal cavity of mice in groups F2-F3 and F6 6 hours after drug administration. Furthermore, the lipid composition for in vivo nucleic acid delivery in group F3 showed higher expression efficiency in the nasal cavity at 6 hours compared to groups F2 and F6.

[0173] Based on the expression levels of lipid compositions used for in vivo nucleic acid delivery in cells and in vivo, the expression level of lipid compositions using DOTAP as a structural lipid for in vivo nucleic acid delivery in group F3 was higher than that of lipid compositions using DOPE or DSPC as structural lipids for in vivo nucleic acid delivery (groups F2 and F6).

[0174] Example 10

[0175] The lipid compositions F2-F3 and F6 for in vivo nucleic acid delivery prepared in Examples 4-5 and Example 9 were used. The particle size, PDI, and Zeta potential of the formulations were measured using a particle size analyzer. The encapsulation efficiency of the formulations was then measured using a fluorescent dye. The results are shown in Table 2.

[0176] Table 2

[0177] preparation Particle size (nm) PDI Zeta potential (mV) Encapsulation efficiency (%) F6 79 0.18 3.03 98.9 F2 79 0.16 -1.41 96.8 F3 79 0.14 5.92 97.3

[0178] Example 11

[0179] A lipid composition F7 for in vivo delivery of nucleic acids was prepared according to the method described in Example 6, wherein the lipids, by molar percentage, are 49.1% cationic lipid of Formula 2, 13.9% structural lipid DOTAP, 34.1% cholesterol, and 2.9% polyethylene glycol 2000.

[0180] A lipid composition F8 for in vivo delivery of nucleic acids was prepared according to the method described in Example 6, wherein the lipids, by molar percentage, are 49.1% cationic lipid of Formula 2, 27.9% structural lipid DOTAP, 20.1% cholesterol, and 2.9% polyethylene glycol 2000.

[0181] The lipid composition F3 for in vivo nucleic acid delivery prepared in Example 4 and the lipid compositions F7-8 for in vivo nucleic acid delivery prepared in this example were used to detect the delivery efficiency in cells and in mice according to the method described in Example 7. In the detection of delivery efficiency in mice, the mRNA concentration in preparations F3, F7 and F8 was adjusted to 900 μg / mL with 1×PBS buffer (pH 7.4 ± 0.05).

[0182] Results of cell delivery efficiency assay are shown below Figure 7 Compared to the negative control, the lipid compositions for in vivo nucleic acid delivery in groups F3, F7, and F8 were successfully expressed in cells. Among them, the lipid composition for in vivo nucleic acid delivery in group F8 showed higher expression efficiency in cells than the other groups.

[0183] The fluorescence detection results 6 hours after drug administration are shown in the figures below. Figure 8 and 9 .

[0184] from Figure 8 and Figure 9 As can be seen above, luciferin expression was observed in the nasal cavity of mice in groups F3, F7, and F8 6 hours after drug administration. Furthermore, the lipid composition for in vivo nucleic acid delivery in group F8 showed higher expression efficiency in the nasal cavity at 6 hours compared to the other groups.

[0185] Based on the expression levels of lipid compositions used for in vivo nucleic acid delivery in cells and in vivo, the expression level of lipid compositions used for in vivo nucleic acid delivery in group F8 was higher than that in other groups.

[0186] Example 12

[0187] The lipid compositions F3 and F7-F8 for in vivo nucleic acid delivery prepared in Examples 4 and 11 were used, and the particle size, PDI, and Zeta potential of the formulations were measured using a particle size analyzer. The encapsulation efficiency of the formulations was then measured using a fluorescent dye. The results are shown in Table 3.

[0188] Table 3

[0189] preparation Particle size (nm) PDI Zeta potential (mV) Encapsulation efficiency (%) F3 79 0.14 5.92 97.3 F7 70 0.19 12.26 98.5 F8 86 0.08 16.71 99.7

[0190] Example 13

[0191] A lipid composition F9 for in vivo delivery of nucleic acids was prepared according to the method described in Example 6, wherein the lipids, by molar percentage, are 49.1% cationic lipid of Formula 2, 27.9% structural lipid DOTAP, 22.0% cholesterol, and 1.0% polyethylene glycol 2000.

[0192] A lipid composition F10 for in vivo delivery of nucleic acids was prepared according to the method described in Example 6, wherein the lipids, by molar percentage, are 49.1% cationic lipid of Formula 2, 27.9% structural lipid DOTAP, 18.2% cholesterol, and 4.8% polyethylene glycol 2000.

[0193] The lipid composition F8 for in vivo nucleic acid delivery prepared in Example 11 and the lipid compositions F9-10 for in vivo nucleic acid delivery prepared in this example were used to detect the delivery efficiency in cells and in mice according to the method described in Example 7. In the detection of delivery efficiency in mice, the mRNA concentration in preparations F8-F10 was adjusted to 900 μg / mL with 1×PBS buffer (pH 7.4 ± 0.05).

[0194] Results of cell delivery efficiency assay are shown below Figure 10 Compared to the negative control, the lipid compositions for in vivo nucleic acid delivery in groups F8–F10 were successfully expressed in cells. The lipid composition for in vivo nucleic acid delivery in group F8 showed higher expression efficiency in cells than the other groups.

[0195] The fluorescence detection results 6 hours after drug administration are shown in the figures below. Figure 11 and 12 .

[0196] from Figure 11 and Figure 12 As can be seen above, luciferin expression was observed in the nasal cavity of mice in groups F8–F10 6 hours after drug administration. Furthermore, the lipid composition for in vivo nucleic acid delivery in group F8 showed higher expression efficiency in the nasal cavity at 6 hours compared to other groups.

[0197] Based on the expression levels of lipid compositions used for in vivo nucleic acid delivery in cells and in vivo, the expression level of lipid compositions used for in vivo nucleic acid delivery in group F8 was higher than that in other groups.

[0198] Example 14

[0199] The lipid compositions F8-F10 for in vivo nucleic acid delivery prepared in Examples 11 and 13 were used, and the particle size, PDI, and Zeta potential of the formulations were measured using a particle size analyzer. The encapsulation efficiency of the formulations was then measured using a fluorescent dye. The results are shown in Table 4.

[0200] Table 4

[0201] preparation Particle size (nm) PDI Zeta potential (mV) Encapsulation efficiency (%) F8 86 0.08 16.71 99.7 F9 102 0.06 15.87 98.7 F10 106 0.28 8.68 96.4

[0202] Example 15

[0203] This embodiment provides a lipid composition for in vivo delivery of nucleic acids, comprising mRNA encoding the RSV pre-fusion F protein, wherein the mRNA comprises, from the 5′ to the 3′ end, a 5′ UTR, an ORF region, a 3′ UTR, and a poly(A) tail. The nucleotide sequence of the 5′ UTR is shown in SEQ ID NO.1, the nucleotide sequence of the 3′ UTR is shown in SEQ ID NO.2, and the nucleotide sequence of the poly(A) tail is shown in SEQ ID NO.3.

[0204] The preparation method is as follows:

[0205] (a) Dissolve the RNA in a citrate buffer at pH 4 and adjust the concentration to 0.1 mg / mL to obtain the aqueous phase.

[0206] (b) Dissolve cationic lipids, structural lipids, cholesterol and polyethylene glycol lipids in anhydrous ethanol according to the formulation amount, and adjust the concentration of lipid components in the organic phase to 6 mg / mL to obtain the organic phase.

[0207] (c) The aqueous phase from step (a) and the organic phase from step (b) are mixed at a volume ratio of 1:3 using a microfluidic device at a flow rate of 12 mL / min. The mixture is immediately diluted 100 times with a mixed solution and the ethanol component in the solution is removed by tangential flow filtration (TFF). The mixture is then concentrated to obtain a lipid composition for in vivo delivery of nucleic acids.

[0208] The lipid composition for in vivo delivery of nucleic acids comprises, by molar percentage, 49.1% cationic lipid of Formula 1, 6.9% structural lipid DSPC, 41.1% cholesterol, and 2.9% polyethylene glycol 2000. The amino acid sequence of the pre-fusion F protein of RSV encoded by mRNA is shown in SEQ ID NO.5, and the nucleotide sequence of the ORF region is shown in SEQ ID NO.4. The lipid composition F11 for in vivo delivery of nucleic acids was prepared.

[0209] The lipid composition for in vivo delivery of nucleic acids comprises, by molar percentage, 49.1% cationic lipid of Formula 2, 27.9% structural lipid DOTAP, 20.1% cholesterol, and 2.9% polyethylene glycol 2000. The amino acid sequence of the pre-fusion F protein of RSV encoded by the mRNA is shown in SEQ ID NO.5, and the nucleotide sequence of the ORF region is shown in SEQ ID NO.4. The lipid composition F12 for in vivo delivery of nucleic acids was prepared.

[0210] The lipid composition for in vivo delivery of nucleic acids comprises, by molar percentage, 49.1% cationic lipid of Formula 2, 27.9% structural lipid DOTAP, 20.1% cholesterol, and 2.9% polyethylene glycol 2000. The amino acid sequence of the pre-fusion F protein of RSV encoded by mRNA is shown in SEQ ID NO.7, and the nucleotide sequence of the ORF region is shown in SEQ ID NO.6. The lipid composition F13 for in vivo delivery of nucleic acids was prepared.

[0211] Example 16

[0212] Female Balb / c mice, 6 weeks old and weighing 20-25g, were purchased from Zhuhai Beston Biotechnology Co., Ltd. They were randomly divided into groups of 5.

[0213] Take the lipid compositions F11-F13 prepared in Example 15 for in vivo delivery of nucleic acids and adjust the mRNA concentration in preparations F11-F13 to 900 μg / mL with 1×PBS buffer (pH 7.4 ± 0.05).

[0214] Immunological experiment of intranasal administration (nasal drip): There were PBS negative control group, intramuscular injection group of preparation F11, intranasal drip group of preparation F11, intramuscular injection group of preparation F12, intranasal drip group of preparation F12, intramuscular injection group of preparation F13, and intranasal drip group of preparation F13.

[0215] A two-immunization program was adopted, with the first administration dated as day D0, and the second administration dated 7 days after the first administration. Blood was collected 7 days after the second administration to separate serum, and bronchoalveolar lavage fluid and nasal lavage fluid were collected.

[0216] Serum-specific IgG titers were detected, as well as serum, bronchoalveolar lavage fluid, and nasal lavage fluid-specific IgA titers.

[0217] The neutralizing activity assay (specific IgG titer and specific IgA assay) of serum (or bronchoalveolar lavage fluid, or nasal lavage fluid) for lipid compositions used for in vivo nucleic acid delivery is as follows:

[0218] a) Dilute the antigen with PBS and add it to the ELISA plate. Incubate overnight, wash, add 2% bovine serum albumin solution, and incubate in an incubator.

[0219] b) Wash the microplate with phosphate-Tween buffer and shake off the liquid in the wells. Add all samples to the microplate after serial dilution with phosphate-Tween buffer, incubate, and then wash.

[0220] c) Add 100 μL of goat anti-mouse IgG or IgA to each well of the ELISA plate, incubate, and then wash with phosphate-Tween buffer.

[0221] d) Add 100 μL TMB of chromogenic solution to each well of the microplate, add the prepared stop solution (2 M H2SO4), and read the OD value at 450 nm on the microplate reader.

[0222] The serum-specific IgG and IgA titers of lipid compositions F11–F13 used for in vivo nucleic acid delivery are shown in the table below. Figure 13 The results of specific IgA titers in bronchoalveolar lavage fluid and nasal lavage fluid of lipid compositions F11–F13 used for in vivo nucleic acid delivery are shown in [the table below]. Figure 14 .

[0223] from Figures 13-14 As can be seen above, the serum-specific IgG, bronchoalveolar lavage fluid and nasal lavage fluid titers, and serum-specific IgA titers of lipid composition F12 for in vivo nucleic acid delivery are all higher than those of other groups. This indicates that the delivery efficiency of lipid composition F12 for in vivo nucleic acid delivery is higher than that of lipid composition F11 for in vivo nucleic acid delivery, and that the mRNA (nucleotide sequence of the ORF region as shown in SEQ ID NO.4) encoding the RSV pre-fusion F protein (amino acid sequence SEQ ID NO.5) contained in lipid composition F12 for in vivo nucleic acid delivery can stimulate better immunogenicity.

[0224] Example 17

[0225] The lipid compositions F11-F13 prepared in Example 15 for in vivo nucleic acid delivery were used, and the particle size, PDI, and Zeta potential of the formulations were measured using a particle size analyzer. The encapsulation efficiency of the formulations was then measured using a fluorescent dye. The results are shown in Table 5.

[0226] Table 5

[0227]

[0228] Example 18

[0229] Female Balb / c mice, 6 weeks old and weighing 20-25g, were purchased from Zhuhai Beston Biotechnology Co., Ltd. They were randomly divided into groups of 5.

[0230] Take the lipid compositions F11 and F12 prepared in Example 15 for in vivo delivery of nucleic acids, and adjust the mRNA concentration in formulations F11 and F12 to 500 μg / mL with 1×PBS buffer (pH 7.4 ± 0.05).

[0231] Nebulized inhalation immunoassay: A PBS negative control group, low / medium / high dose groups of formulation F11 (nebulized inhalation), and low / medium / high dose groups of formulation F12 (nebulized inhalation) were established. The dosage for the low-dose groups of formulations F11 and F12 was 10 μg mRNA, the dosage for the medium-dose groups was 50 μg mRNA, and the dosage for the high-dose groups was 200 μg mRNA.

[0232] A two-immunization program was employed, with the first dose administered on day D0, followed by the second dose on day 7. Blood was collected 7 days after the second immunization to separate serum, and nasal lavage fluid was collected. All lung cells were collected to verify the cellular immune response.

[0233] I. Detection of serum-specific IgG titers and detection of serum and nasal lavage fluid-specific IgA titers.

[0234] The detection methods for specific IgG titer and specific IgA titer are described in Example 16.

[0235] The serum-specific IgG titer results and nasal lavage fluid-specific IgA titer results for lipid compositions F11–F12 used for in vivo nucleic acid delivery are shown in [reference needed]. Figure 15 .

[0236] from Figure 15 As can be seen above, the specific IgA titers in serum IgG and nasal lavage fluid of lipid composition F12 for in vivo nucleic acid delivery were higher than those in other groups, indicating that the delivery efficiency of lipid composition F12 for in vivo nucleic acid delivery was higher than that of lipid composition F11 for in vivo nucleic acid delivery.

[0237] II. Detection of Lung Lymphocytes in Mice

[0238] All lung cells were collected from mice in the immunized group 14 days after the first immunization (7 days after the second immunization). Flow cytometry was used to detect CD3+CD4+ and CD3+CD8+ T lymphocytes. The specific procedures are as follows:

[0239] a) Remove mouse lungs, cut them into pieces, digest them, pass the lung cell suspension through a cell sieve, centrifuge and collect the precipitate.

[0240] b) Add erythrocyte lysis buffer, let stand, and then add RPMI-1640 basal medium to terminate the reaction. Centrifuge at room temperature and collect the precipitate.

[0241] c) Wash with RPMI 1640 basal medium and centrifuge.

[0242] d) Add Staining Buffer, then add 1 μg BD Fc block / 10^6 cells, and incubate at 4°C for 15 min. Centrifuge and retain the pellet.

[0243] e) After washing the cells, stain the cell surface, resuspend in Staining Buffer, and analyze using a flow cytometer.

[0244] The results of the detection of mouse lung lymphocytes are shown in the figure. Figure 16 .

[0245] from Figure 16 As can be seen above, lipid composition F12 for in vivo delivery of nucleic acids is more effective in enhancing humoral immunity than lipid composition F11 for in vivo delivery of nucleic acids.

[0246] Example 19

[0247] The lipid compositions F11-F12 prepared in Example 18 for in vivo nucleic acid delivery were used, and the particle size, PDI, and Zeta potential of the formulations were measured using a particle size analyzer. The encapsulation efficiency of the formulations was then measured using a fluorescent dye. The results are shown in Table 6.

[0248] Table 6

[0249] preparation Particle size (nm) PDI Zeta potential (mV) Encapsulation efficiency (%) Collection method F11 75.74 0.14 3.69 96.61 Before atomization F11 274.70 0.26 -13.04 22.91 After atomization F12 61.03 0.11 10.63 98.44 Before mold growth F12 329.00 0.42 10.47 98.10 After mold

[0250] As shown in Table 6, the encapsulation efficiency of lipid composition F11 for in vivo nucleic acid delivery decreased sharply after nebulization, and the zeta potential also changed significantly; while the encapsulation efficiency and zeta potential of lipid composition F12 for in vivo nucleic acid delivery remained relatively stable before and after nebulization. Therefore, lipid composition F12 for in vivo nucleic acid delivery is more suitable for inhalation administration.

Claims

1. A lipid composition for in vivo delivery of nucleic acid, characterized in that The lipid composition for in vivo delivery of nucleic acid comprises lipid nanoparticles and nucleic acid encapsulated by the lipid nanoparticles.

2. The preparation according to claim 1, characterized in that The lipid nanoparticle comprises 25.0-50.0 mol% of a cationic lipid, 6.0-40.0 mol% of a phospholipid, 20.0-47.0 mol% of a structural lipid, and 1.0-5.0 mol% of a polyethylene glycol-modified lipid, based on the total amount of all lipids in the lipid nanoparticle; Preferably, the lipid nanoparticle comprises 25.0-50.0 mol% of cationic lipids, 6.0-30.0 mol% of phospholipids, 20.0-47.0 mol% of structural lipids and 1.0-5.0 mol% of polyethylene glycol-modified lipids, based on the total amount of all lipids in the lipid nanoparticle; Preferably, the lipid nanoparticles contain 49.1 mol % of cationic lipids, 27.9 mol % of phospholipids, 20.1 mol % of structural lipids and 2.9 mol % of polyethylene glycol-modified lipids, based on the total amount of all lipids in the lipid nanoparticles.

3. The preparation according to claim 2, characterized in that The cationic lipid is selected from at least one compound of Formula 1, Formula 2, Formula 3, and Formula 4; Preferably, the cationic lipid is a compound as shown in Formula 2; Preferably, the structural lipid is selected from at least one of cholesterol, coprosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatine, tomatin, ursolic acid, and α-tocopherol; preferably, the structural lipid is cholesterol; Preferably, the phospholipid is selected from at least one of DSPC, DOPE, DLPC, DMPC, DOPC, DPPC, DUPC, POPC, DOPG, DPPG, DPPE, DMPE, DSPE, and DOTAP; preferably, the phospholipid is DOTAP; Preferably, the polyethylene glycol-modified lipid is selected from at least one of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, and PEG-modified dialkylglycerol; preferably, the PEG lipid is at least one of PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, PEG-DSPE, ceramide-PEG2000 or Chol-PEG2000, PEG2000; preferably, the PEG lipid is PEG2000.

4. The preparation according to claim 1, characterized in that The nucleic acid comprises a DNA molecule and / or an RNA molecule; Preferably, the DNA molecules include chain DNA molecules and / or circular DNA molecules; Preferably, the RNA molecule comprises mRNA or circular RNA.

5. The preparation according to claim 4, characterized in that The mRNA molecule comprises an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown in one of Seq ID NO.4 or Seq ID NO.6; Preferably, the mRNA molecule comprises an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown in Seq ID NO.

4.

6. The preparation according to claim 4, characterized in that The lipid composition for in vivo delivery of nucleic acids is used for administration to the nasal cavity and respiratory mucosa; Preferably, the nasal administration includes nasal drip, nasal spray administration or nasal inhalation.

7. The preparation according to claim 1, characterized in that The average particle size of the lipid nanoparticles is 60nm to 300nm; Preferably, the average particle size of the lipid nanoparticles is 80nm to 100nm; preferably, the average particle size of the lipid nanoparticles is 80nm to 90nm; The polydispersity index of the lipid nanoparticles is 0 to 0.25; preferably, the polydispersity index of the lipid nanoparticles is 0.00 to 0.10; The Zeta potential of the lipid nanoparticles is -20mV to +20mV; preferably, the Zeta potential of the lipid nanoparticles is +10mV to +20mV.

8. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the lipid composition for in vivo delivery of nucleic acid as claimed in claims 1 to 6, and optionally a pharmaceutically acceptable excipient; Preferably, the pharmaceutical composition is used for administration to the nasal cavity or respiratory mucosa.

9. The preparation according to claim 8, characterized in that The excipient is 1×PBS buffer, and the buffer has a pH of 7.4±0.

05.

10. The preparation according to claim 9, characterized in that The pharmaceutical composition is used for nasal administration, and the nucleic acid concentration in the pharmaceutical composition is 800-1000 μg / mL; The pharmaceutical composition is used for administration to the respiratory mucosa, and the nucleic acid concentration in the pharmaceutical composition is 400-600 μg / mL.